Bioadaptives, Inc. (BDPT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2620 REGATTA DRIVE LAS VEGAS, NV 89128 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 61 | 25 | 83 | 5 | 13 | 5 | |||
| Cash and cash equivalents | 61 | 25 | 83 | 5 | 12 | 0 | |||
| Short-term investments | 0 | 0 | 0 | 1 | 5 | ||||
| Inventory, net of allowances, customer advances and progress billings | 15 | 9 | 5 | 14 | 11 | ||||
| Inventory | 15 | 9 | 5 | 14 | 11 | ||||
| Prepaid expense | 10 | 1 | |||||||
| Deposits current assets | 2 | ||||||||
| Other undisclosed current assets | 3 | ||||||||
| Total current assets: | 89 | 34 | 89 | 19 | 24 | 7 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1 | ||||||||
| Intangible assets, net (including goodwill) | 15 | 3 | 60 | ||||||
| Intangible assets, net (excluding goodwill) | 15 | 3 | 60 | ||||||
| Other undisclosed noncurrent assets | 0 | ||||||||
| Total noncurrent assets: | 15 | 3 | 60 | 1 | |||||
| TOTAL ASSETS: | 104 | 37 | 149 | 19 | 24 | 7 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 444 | 410 | 248 | 88 | 30 | 34 | |||
| Accounts payable | 3 | 7 | 34 | ||||||
| Accrued liabilities | 138 | 1 | 63 | 0 | |||||
| Other undisclosed accounts payable and accrued liabilities | 302 | 402 | 185 | 88 | 30 | ||||
| Debt | 322 | 382 | 403 | 405 | 7 | ||||
| Derivative instruments and hedges, liabilities | 978 | 687 | 557 | 827 | |||||
| Due to related parties | ✕ | ✕ | 10 | 34 | 78 | 50 | 151 | ||
| Other undisclosed current liabilities | 8 | 777 | 25 | ||||||
| Total current liabilities: | 1,751 | 1,489 | 1,242 | 1,398 | 864 | 211 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 1,751 | 1,489 | 1,242 | 1,398 | 864 | 211 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,647) | (1,452) | (1,093) | (1,379) | (840) | (203) | |||
| Common stock | 90 | 25 | 5 | 2 | 2 | 1 | |||
| Additional paid in capital | 6,527 | 6,075 | 5,558 | 4,225 | 3,917 | 2,673 | |||
| Accumulated other comprehensive loss | (57) | ||||||||
| Accumulated deficit | (8,264) | (7,552) | (6,656) | (5,606) | (4,759) | (2,821) | |||
| Other undisclosed equity, attributable to parent | 1 | 0 | 0 | ||||||
| Total equity: | (1,647) | (1,452) | (1,093) | (1,379) | (840) | (203) | |||
| TOTAL LIABILITIES AND EQUITY: | 104 | 37 | 149 | 19 | 24 | 7 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 29 | 17 | 20 | 16 | 10 | |||
| Cost of revenue | (18) | (10) | (10) | (10) | (5) | |||
| Other undisclosed gross profit | ||||||||
| Gross profit: | 11 | 7 | 10 | 6 | 5 | |||
| Operating expenses | (240) | (429) | (646) | (260) | (239) | (227) | ||
| Other operating expense, net (Other Expenses) | (414) | (593) | ||||||
| Other undisclosed operating income | ||||||||
| Operating loss: | (229) | (422) | (1,050) | (847) | (234) | (227) | ||
| Nonoperating income (expense) | (484) | (474) | 1,376 | (5) | (0) | |||
| Investment income, nonoperating | 90 | (198) | ||||||
| Gain on sale of leased assets, net, operating leases | 1,286 | |||||||
| Other nonoperating expense | (484) | (474) | ||||||
| Interest and debt expense | (13) | (289) | (323) | 133 | 199 | (0) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (726) | (1,185) | 3 | (715) | (40) | (228) | ||
| Other undisclosed loss from continuing operations before income taxes | (133) | (199) | ||||||
| Income (loss) from continuing operations before income taxes: | (726) | (1,185) | 3 | (847) | (239) | (228) | ||
| Other undisclosed income (loss) from continuing operations | 13 | 289 | ||||||
| Income (loss) from continuing operations: | (712) | (896) | 3 | (847) | (239) | (228) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 3 | (847) | (239) | (228) | |
| Other undisclosed net income | ||||||||
| Net income (loss): | (712) | (896) | 3 | (847) | (239) | (228) | ||
| Other undisclosed net income (loss) attributable to parent | (1,053) | 0 | ||||||
| Net loss attributable to parent: | (712) | (896) | (1,050) | (847) | (239) | (227) | ||
| Preferred stock dividends and other adjustments | 194 | |||||||
| Net loss available to common stockholders, basic: | (712) | (896) | (856) | (847) | (239) | (227) | ||
| Interest on convertible debt | 6 | 12 | ||||||
| Net loss available to common stockholders, diluted: | (706) | (884) | (856) | (847) | (239) | (227) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (712) | (896) | 3 | (847) | (239) | (228) | ||
| Comprehensive income (loss): | (712) | (896) | 3 | (847) | (239) | (228) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (25) | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (712) | (896) | 3 | (847) | (239) | (253) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.